Your browser doesn't support javascript.
loading
Apixaban versus warfarin in evaluation of progression of atherosclerotic and calcified plaques (prospective randomized trial).
Win, Theingi Tiffany; Nakanishi, Rine; Osawa, Kazuhiro; Li, Dong; Susaria, Shriraj S; Jayawardena, Eranthi; Hamal, Sajad; Kim, Michael; Broersen, Alexander; Kitslaar, Pieter H; Dailing, Christopher; Budoff, Matthew J.
Afiliación
  • Win TT; Division of Cardiology, Department of Medicine, University of New Mexico, Albuquerque, NM.
  • Nakanishi R; Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA.
  • Osawa K; Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA.
  • Li D; Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA.
  • Susaria SS; Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA.
  • Jayawardena E; Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA.
  • Hamal S; Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA.
  • Kim M; Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA.
  • Broersen A; Division of Image Processing, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Kitslaar PH; Division of Image Processing, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands; Medis medical systems bv, Leiden, The Netherlands.
  • Dailing C; Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA.
  • Budoff MJ; Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA. Electronic address: mbudoff@labiomed.org.
Am Heart J ; 212: 129-133, 2019 06.
Article en En | MEDLINE | ID: mdl-31002997
Warfarin has been showed to increase vascular calcification. Apixaban, a direct factor Xa inhibitor, has no interaction with vitamin K and its effect on coronary plaques is unknown. We randomized and compared warfarin and apixaban on progression of coronary atherosclerotic plaques measured by coronary computed tomographic angiography in 66 subjects with non-valvular atrial fibrillation over the period of one-year follow up. There was significant higher total, calcified and low attenuation plaque volume in the group randomized to warfarin as compared to apixaban (all P < .05). Greater volume of total (ß2 = 28.54; P = .03), low attenuation plaque (ß2 = 3.58; P = .02) and calcified (ß2 = 14.10; P = .005) plaque progression was observed in the VKA_group.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirazoles / Piridonas / Warfarina / Ensayos Clínicos Controlados Aleatorios como Asunto / Aterosclerosis / Calcificación Vascular Tipo de estudio: Clinical_trials Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Am Heart J Año: 2019 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirazoles / Piridonas / Warfarina / Ensayos Clínicos Controlados Aleatorios como Asunto / Aterosclerosis / Calcificación Vascular Tipo de estudio: Clinical_trials Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Am Heart J Año: 2019 Tipo del documento: Article